BST’s Corporate Mission is to unleash the artist in the surgeon® and be a world leading manufacturer and developer of medical devices and procedures for handling adipose tissue targeting: · the liposuction and body sculpting market; · the bariatric market; and · fat autograft and adipocyte-derived stem cell processing markets. BST's Obesity Control Division is developing minimally invasive medical devices and methods for endoscopic visceral lipectomy, the direct removal of intra-abdominal "belly fat" taught by its three recently granted U.S. patents and its EPO application. These devices and methods have the potential for helping 1.3 Billion obese people about the globe suffering from obesity, metabolic syndrome, and type 2 diabetes mellitus. We believe we can offer a safer and highly effective alternative to current surgical bariatric surgery treatments of obesity.